179
Participants
Start Date
December 13, 2021
Primary Completion Date
March 26, 2026
Study Completion Date
March 26, 2026
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
GEN1047 will be administered as an intravenous infusion. The dose-levels will be determined by the starting dose and the escalation steps taken in the trial.
IEO Istituto Europeo di Oncologia, Milan
Rigshospitalet (Copenhagen University Hospital), Copenhagen
Antwerp University Hospital, Edegem
Hospital Universitary Fundacion Jimenez Diaz, Madrid
Universitair Ziekenhuis Leuven, Leuven
Hospital Universitari Vall d'Hebron, Barcelona
University of Pennsylvania, Philadelphia
Fondazione IRCCS San Gerardo dei Tintori, Monza
CHU de Besancon, Besançon
MD Anderson Cancer Center, Madrid
Hospital Ruber Internacional, Madrid
Centro Oncologico Clara Campal, Madrid
Clinica Universidad de Navarra, Pamplona
Institut du Cancer de Montpellier, Montpellier
Sarah Cannon Research Institute, Nashville
Case Western Reserve University, Cleveland
Barbara Ann Karmanos Cancer Institute, Detroit
Centre Léon Bérard, Lyon
Institut Gustave Roussy, Villejuif
Institut Curie, Paris
UCLA Department of Medicine Hematology Oncology, Los Angeles
Yale University - Yale Cancer Center, New Haven
Institut Bergonié, Bordeaux
Hôpital Cochin, Paris
CHU Poitiers - Hôpital la Milétrie, Poitiers
Institut Claudius Regaud, Toulouse
Med-Polonia Sp. z o.o, Poznan
Hospital Clinic de Barcelona, Barcelona
NEXT Oncology Madrid, Madrid
Hospital Clinico Universitario de Valencia, Valencia
University Medical Center Groningen, Groningen
Radboudumc, Nijmegen
Erasmus Medisch Centrum, Rotterdam
St Bartholomews Hospital, London
University College London Hospital, London
The Christie Hospital, Manchester
Lead Sponsor
Genmab
INDUSTRY